You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTeriflunomide
Accession NumberDB08880
TypeSmall Molecule
GroupsApproved
DescriptionTeriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
Structure
Thumb
Synonyms
(Z)-2-Cyano-alpha,alpha,alpha-trifluoro-3-hydroxy-P-crotonotoluidide
a 77-1726
a 771726
Aubagio
HMR 1726
HMR1726
Teriflunomida
Teriflunomidum
External Identifiers
  • A-771726
  • HMR1726
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AubagioFilm-coated tablet14 mgOral useSanofi Aventis Groupe2013-08-26Not applicableEu
Aubagiotablet, film coated14 mg/1oralGenzyme Corp.2013-05-01Not applicableUs
AubagioFilm-coated tablet14 mgOral useSanofi Aventis Groupe2013-08-26Not applicableEu
Aubagiotablet, film coated7 mg/1oralGenzyme Corp.2013-05-01Not applicableUs
AubagioFilm-coated tablet14 mgOral useSanofi Aventis Groupe2013-08-26Not applicableEu
Aubagiotablet14 mgoralGenzyme Canada A Division Of Sanofi Aventis Canada Inc2013-11-15Not applicableCanada
AubagioFilm-coated tablet14 mgOral useSanofi Aventis Groupe2013-08-26Not applicableEu
AubagioFilm-coated tablet14 mgOral useSanofi Aventis Groupe2013-08-26Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII1C058IKG3B
CAS number163451-81-8
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Taxonomy
ClassificationNot classified
Pharmacology
IndicationUsed in the treatment of relapsing forms of multiple sclerosis (MS).
PharmacodynamicsTeriflunomide is an immunomodulatory agent that decreases the amount of activated CNS lymphocytes, which results in anti-inflammatory and antiproliferative effects.
Mechanism of actionThe exact mechanism by which teriflunomide acts in MS is not known. What is known is that teriflunomide prevents pyrimidine synthesis by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase, and this may be involved in its immunomodulatory effect in MS.
Related Articles
AbsorptionAfter oral administration of teriflunomide, maximum plasma concentrations are reached, on average, in 1-4 hours.
Volume of distribution

After a single intravenous dose, the volume of distribution is 11 L.

Protein bindingTeriflunomide is extensively plasma protein bound(>99%).
Metabolism

Teriflunomide mainly undergoes hydrolyis to minor metabolites. Other minor metabolic pathways include oxidation, N-acetylation and sulfate conjugation. Teriflunomide is not metabolized by CYP450 or flavin monoamine oxidase.

Route of eliminationTeriflunomide is eliminated unchanged and mainly through bile. Specifically 37.5% is eliminated in the feces and 22.6% in urine.
Half lifeThe median half-life is 18 to 19 days.
Clearance

After a single IV dose, teriflunomide has a total body clearance of 30.5 mL/h.

ToxicityTeriflunomide is contraindicated in pregnant women or women of childbearing age due to the risk of teratogenicity. Teriflunomide is also contraindicated in severe hepatic impairment due to reports of hepatotoxicity, hepatic failure, and death.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Film-coated tabletOral use14 mg
Tabletoral14 mg
Tablet, film coatedoral14 mg/1
Tablet, film coatedoral7 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6794410 No2002-04-152022-04-15Us
US8802735 No2010-09-142030-09-14Us
US9186346 No2014-02-042034-02-04Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySoluble in DMSO (practically insoluble in water).From FDA label.
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
References
Synthesis Reference

Keshav Deo, Samir Patel, Snehal Dhol, Sunil Sanghani, Vishal Ray, " PROCESS FOR PREPARING TERIFLUNOMIDE." U.S. Patent US20110092727, issued April 21, 2011.

US20110092727
General References
  1. O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R: A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006 Mar 28;66(6):894-900. [PubMed:16567708 ]
  2. Tallantyre E, Evangelou N, Constantinescu CS: Spotlight on teriflunomide. Int MS J. 2008 Jun;15(2):62-8. [PubMed:18782502 ]
External Links
ATC CodesL04AA31
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (527 KB)
MSDSDownload (124 KB)
Interactions
Drug Interactions
Drug
AbciximabTeriflunomide may increase the anticoagulant activities of Abciximab.
AcebutololTeriflunomide may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Teriflunomide.
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Teriflunomide.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Teriflunomide.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Teriflunomide.
AciclovirThe serum concentration of Aciclovir can be increased when it is combined with Teriflunomide.
Activated charcoalThe serum concentration of Teriflunomide can be decreased when it is combined with Activated charcoal.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Teriflunomide.
Adefovir DipivoxilThe serum concentration of Adefovir Dipivoxil can be increased when it is combined with Teriflunomide.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Teriflunomide.
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Teriflunomide.
Alendronic acidThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Alendronic acid.
AliskirenTeriflunomide may decrease the antihypertensive activities of Aliskiren.
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Teriflunomide.
AlosetronThe serum concentration of Alosetron can be decreased when it is combined with Teriflunomide.
AlprenololTeriflunomide may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Teriflunomide.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Teriflunomide.
AmikacinTeriflunomide may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideTeriflunomide may decrease the antihypertensive activities of Amiloride.
Aminohippuric acidThe serum concentration of Aminohippuric acid can be increased when it is combined with Teriflunomide.
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Teriflunomide.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Teriflunomide.
AmiodaroneThe serum concentration of Amiodarone can be decreased when it is combined with Teriflunomide.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Teriflunomide.
AmodiaquineThe metabolism of Amodiaquine can be decreased when combined with Teriflunomide.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Teriflunomide.
AnagrelideThe serum concentration of Anagrelide can be decreased when it is combined with Teriflunomide.
AncrodTeriflunomide may increase the anticoagulant activities of Ancrod.
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Teriflunomide.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Teriflunomide.
Antithrombin III humanTeriflunomide may increase the anticoagulant activities of Antithrombin III human.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Teriflunomide.
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Teriflunomide.
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Teriflunomide.
ArdeparinTeriflunomide may increase the anticoagulant activities of Ardeparin.
ArgatrobanTeriflunomide may increase the anticoagulant activities of Argatroban.
ArotinololTeriflunomide may decrease the antihypertensive activities of Arotinolol.
ASA404The serum concentration of ASA404 can be decreased when it is combined with Teriflunomide.
AsenapineThe serum concentration of Asenapine can be decreased when it is combined with Teriflunomide.
AtenololTeriflunomide may decrease the antihypertensive activities of Atenolol.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Teriflunomide.
AV650The serum concentration of AV650 can be decreased when it is combined with Teriflunomide.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Teriflunomide.
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Teriflunomide.
AzelastineThe serum concentration of Azelastine can be decreased when it is combined with Teriflunomide.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Teriflunomide.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Teriflunomide.
BalsalazideTeriflunomide may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Teriflunomide.
BecaplerminTeriflunomide may increase the anticoagulant activities of Becaplermin.
BefunololTeriflunomide may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Teriflunomide.
BendamustineThe serum concentration of Bendamustine can be decreased when it is combined with Teriflunomide.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Teriflunomide.
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Teriflunomide.
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Teriflunomide.
BenzylpenicillinThe serum concentration of Benzylpenicillin can be increased when it is combined with Teriflunomide.
BeraprostThe metabolism of Beraprost can be decreased when combined with Teriflunomide.
BetaxololThe serum concentration of Betaxolol can be decreased when it is combined with Teriflunomide.
BevantololTeriflunomide may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Teriflunomide.
BisoprololTeriflunomide may decrease the antihypertensive activities of Bisoprolol.
BivalirudinTeriflunomide may increase the anticoagulant activities of Bivalirudin.
BopindololTeriflunomide may decrease the antihypertensive activities of Bopindolol.
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Teriflunomide.
BromazepamThe serum concentration of Bromazepam can be decreased when it is combined with Teriflunomide.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Teriflunomide.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Teriflunomide.
BufuralolTeriflunomide may decrease the antihypertensive activities of Bufuralol.
BumetanideTeriflunomide may decrease the diuretic activities of Bumetanide.
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Teriflunomide.
BupranololTeriflunomide may decrease the antihypertensive activities of Bupranolol.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Teriflunomide.
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Teriflunomide.
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Teriflunomide.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Teriflunomide.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Teriflunomide.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Teriflunomide.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Teriflunomide.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Teriflunomide.
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Teriflunomide.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Teriflunomide.
CarboplatinThe serum concentration of Carboplatin can be increased when it is combined with Teriflunomide.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Teriflunomide.
CarmustineThe serum concentration of Carmustine can be decreased when it is combined with Teriflunomide.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Teriflunomide.
CarteololTeriflunomide may decrease the antihypertensive activities of Carteolol.
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Teriflunomide.
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Teriflunomide.
CefacetrileThe serum concentration of Cefacetrile can be increased when it is combined with Teriflunomide.
CefazolinThe serum concentration of Cefazolin can be increased when it is combined with Teriflunomide.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Teriflunomide.
CeliprololTeriflunomide may decrease the antihypertensive activities of Celiprolol.
CephalexinThe serum concentration of Cephalexin can be increased when it is combined with Teriflunomide.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Teriflunomide.
CertoparinTeriflunomide may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Teriflunomide.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Teriflunomide.
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Teriflunomide.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Teriflunomide.
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Teriflunomide.
CholesterolThe serum concentration of Cholesterol can be increased when it is combined with Teriflunomide.
CholestyramineThe serum concentration of Teriflunomide can be decreased when it is combined with Cholestyramine.
Cholic AcidThe serum concentration of Cholic Acid can be increased when it is combined with Teriflunomide.
CidofovirThe serum concentration of Cidofovir can be increased when it is combined with Teriflunomide.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Teriflunomide.
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Teriflunomide.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Teriflunomide.
CinacalcetThe serum concentration of Cinacalcet can be decreased when it is combined with Teriflunomide.
CinnarizineThe serum concentration of Cinnarizine can be decreased when it is combined with Teriflunomide.
CisaprideThe serum concentration of Cisapride can be decreased when it is combined with Teriflunomide.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Teriflunomide.
Citric AcidTeriflunomide may increase the anticoagulant activities of Citric Acid.
CladribineThe serum concentration of Cladribine can be increased when it is combined with Teriflunomide.
ClenbuterolThe serum concentration of Clenbuterol can be decreased when it is combined with Teriflunomide.
ClevidipineThe serum concentration of Clevidipine can be decreased when it is combined with Teriflunomide.
ClodronateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Clodronate.
ClofarabineThe serum concentration of Clofarabine can be increased when it is combined with Teriflunomide.
ClomipramineThe serum concentration of Clomipramine can be decreased when it is combined with Teriflunomide.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Teriflunomide.
ClonixinThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Clonixin.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Teriflunomide.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Teriflunomide.
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Teriflunomide.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Teriflunomide.
ColesevelamThe serum concentration of Teriflunomide can be decreased when it is combined with Colesevelam.
ColestipolThe serum concentration of Teriflunomide can be decreased when it is combined with Colestipol.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Teriflunomide.
Cyclic Adenosine MonophosphateThe serum concentration of Cyclic Adenosine Monophosphate can be increased when it is combined with Teriflunomide.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Teriflunomide.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Teriflunomide.
CyclosporineTeriflunomide may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with D-Limonene.
Dabigatran etexilateTeriflunomide may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Teriflunomide.
DacarbazineThe serum concentration of Dacarbazine can be decreased when it is combined with Teriflunomide.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Teriflunomide.
DalteparinTeriflunomide may increase the anticoagulant activities of Dalteparin.
DanaparoidTeriflunomide may increase the anticoagulant activities of Danaparoid.
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Teriflunomide.
DapsoneThe metabolism of Dapsone can be decreased when combined with Teriflunomide.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Teriflunomide.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Teriflunomide.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Teriflunomide.
DeferasiroxThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Deferasirox.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Teriflunomide.
DesipramineThe serum concentration of Desipramine can be decreased when it is combined with Teriflunomide.
DesirudinTeriflunomide may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Desmopressin.
DexfenfluramineThe serum concentration of Dexfenfluramine can be decreased when it is combined with Teriflunomide.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Teriflunomide.
DextranTeriflunomide may increase the anticoagulant activities of Dextran.
Dextran 40Teriflunomide may increase the anticoagulant activities of Dextran 40.
Dextran 70Teriflunomide may increase the anticoagulant activities of Dextran 70.
Dextran 75Teriflunomide may increase the anticoagulant activities of Dextran 75.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Teriflunomide.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Teriflunomide.
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Teriflunomide.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Teriflunomide.
DicoumarolTeriflunomide may increase the anticoagulant activities of Dicoumarol.
DidanosineThe serum concentration of Didanosine can be increased when it is combined with Teriflunomide.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Teriflunomide.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Teriflunomide.
DihydrostreptomycinTeriflunomide may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Teriflunomide.
DinoprostoneThe serum concentration of Dinoprostone can be increased when it is combined with Teriflunomide.
DiphenhydramineThe serum concentration of Diphenhydramine can be decreased when it is combined with Teriflunomide.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Teriflunomide.
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Teriflunomide.
DoxepinThe serum concentration of Doxepin can be decreased when it is combined with Teriflunomide.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Teriflunomide.
DrospirenoneTeriflunomide may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Droxicam.
DuloxetineThe serum concentration of Duloxetine can be decreased when it is combined with Teriflunomide.
Edetic AcidTeriflunomide may increase the anticoagulant activities of Edetic Acid.
EdoxabanTeriflunomide may increase the anticoagulant activities of Edoxaban.
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Teriflunomide.
EltrombopagThe serum concentration of Teriflunomide can be increased when it is combined with Eltrombopag.
EluxadolineThe serum concentration of Eluxadoline can be increased when it is combined with Teriflunomide.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Teriflunomide.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Teriflunomide.
EnoxaparinTeriflunomide may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Teriflunomide.
EpirizoleThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Epirizole.
EpirubicinTeriflunomide may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneTeriflunomide may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Teriflunomide.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Teriflunomide.
ErgotamineThe serum concentration of Ergotamine can be decreased when it is combined with Teriflunomide.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Teriflunomide.
EsmololTeriflunomide may decrease the antihypertensive activities of Esmolol.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Teriflunomide.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Teriflunomide.
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Teriflunomide.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Teriflunomide.
Etacrynic acidTeriflunomide may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Teriflunomide.
EthanolThe serum concentration of Ethanol can be decreased when it is combined with Teriflunomide.
Ethyl biscoumacetateTeriflunomide may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Teriflunomide.
EtofenamateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Etofenamate.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Teriflunomide.
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Teriflunomide.
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Teriflunomide.
Evening primrose oilThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Teriflunomide.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Teriflunomide.
FenbufenThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Teriflunomide.
FingolimodTeriflunomide may increase the immunosuppressive activities of Fingolimod.
FlavopiridolThe serum concentration of Flavopiridol can be increased when it is combined with Teriflunomide.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Teriflunomide.
FlunarizineThe serum concentration of Flunarizine can be decreased when it is combined with Teriflunomide.
FlunitrazepamThe serum concentration of Flunitrazepam can be decreased when it is combined with Teriflunomide.
FlunixinThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Flunixin.
FluorouracilThe serum concentration of Fluorouracil can be decreased when it is combined with Teriflunomide.
FluoxetineThe serum concentration of Fluoxetine can be decreased when it is combined with Teriflunomide.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Teriflunomide.
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Teriflunomide.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Teriflunomide.
FluvoxamineThe serum concentration of Fluvoxamine can be decreased when it is combined with Teriflunomide.
Folic AcidThe serum concentration of Folic Acid can be increased when it is combined with Teriflunomide.
Fondaparinux sodiumTeriflunomide may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Teriflunomide.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Teriflunomide.
FosphenytoinThe metabolism of Fosphenytoin can be decreased when combined with Teriflunomide.
FramycetinTeriflunomide may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FrovatriptanThe serum concentration of Frovatriptan can be decreased when it is combined with Teriflunomide.
FurosemideTeriflunomide may decrease the diuretic activities of Furosemide.
Gadoxetic acidThe serum concentration of Gadoxetic acid can be increased when it is combined with Teriflunomide.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Teriflunomide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Teriflunomide.
GenisteinThe serum concentration of Genistein can be decreased when it is combined with Teriflunomide.
GentamicinTeriflunomide may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
GimatecanThe serum concentration of Gimatecan can be increased when it is combined with Teriflunomide.
Glutaric AcidThe serum concentration of Glutaric Acid can be increased when it is combined with Teriflunomide.
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Teriflunomide.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Teriflunomide.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Teriflunomide.
GuanabenzThe serum concentration of Guanabenz can be decreased when it is combined with Teriflunomide.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Teriflunomide.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Teriflunomide.
HeparinTeriflunomide may increase the anticoagulant activities of Heparin.
HesperetinThe serum concentration of Hesperetin can be decreased when it is combined with Teriflunomide.
HexobarbitalThe serum concentration of Hexobarbital can be decreased when it is combined with Teriflunomide.
HirulogTeriflunomide may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Teriflunomide.
HydralazineTeriflunomide may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Teriflunomide.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Teriflunomide.
Hygromycin BTeriflunomide may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Teriflunomide.
IbuproxamThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Teriflunomide.
IdarubicinTeriflunomide may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Teriflunomide.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Teriflunomide.
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Teriflunomide.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Teriflunomide.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Teriflunomide.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Teriflunomide.
ImiquimodThe serum concentration of Imiquimod can be decreased when it is combined with Teriflunomide.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Teriflunomide.
IndenololTeriflunomide may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Teriflunomide.
IndoprofenThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Teriflunomide.
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Teriflunomide.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Teriflunomide.
IsoxicamThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Isoxicam.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Teriflunomide.
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Teriflunomide.
KanamycinTeriflunomide may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Kebuzone.
KetamineThe metabolism of Ketamine can be decreased when combined with Teriflunomide.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Teriflunomide.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Teriflunomide.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Teriflunomide.
LabetalolTeriflunomide may decrease the antihypertensive activities of Labetalol.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Teriflunomide.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Teriflunomide.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Teriflunomide.
LeflunomideThe serum concentration of Leflunomide can be decreased when it is combined with Teriflunomide.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Teriflunomide.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Teriflunomide.
LepirudinTeriflunomide may increase the anticoagulant activities of Lepirudin.
LevobunololTeriflunomide may decrease the antihypertensive activities of Levobunolol.
LevobupivacaineThe serum concentration of Levobupivacaine can be decreased when it is combined with Teriflunomide.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Teriflunomide.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Teriflunomide.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Teriflunomide.
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Teriflunomide.
LiothyronineThe serum concentration of Liothyronine can be increased when it is combined with Teriflunomide.
LiotrixThe serum concentration of Liotrix can be increased when it is combined with Teriflunomide.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Teriflunomide.
LithiumThe serum concentration of Lithium can be increased when it is combined with Teriflunomide.
LomefloxacinThe serum concentration of Lomefloxacin can be decreased when it is combined with Teriflunomide.
LoperamideThe metabolism of Loperamide can be decreased when combined with Teriflunomide.
LoratadineThe metabolism of Loratadine can be decreased when combined with Teriflunomide.
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Teriflunomide.
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Teriflunomide.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Teriflunomide.
LosartanThe metabolism of Losartan can be decreased when combined with Teriflunomide.
LoxoprofenThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Teriflunomide.
LumiracoxibThe serum concentration of Lumiracoxib can be decreased when it is combined with Teriflunomide.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Teriflunomide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Teriflunomide.
MalathionThe serum concentration of Malathion can be decreased when it is combined with Teriflunomide.
MaprotilineThe serum concentration of Maprotiline can be decreased when it is combined with Teriflunomide.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Teriflunomide.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Teriflunomide.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Teriflunomide.
MelatoninThe serum concentration of Melatonin can be decreased when it is combined with Teriflunomide.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Teriflunomide.
MenadioneThe serum concentration of Menadione can be decreased when it is combined with Teriflunomide.
MephenytoinThe serum concentration of Mephenytoin can be decreased when it is combined with Teriflunomide.
MesalazineTeriflunomide may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Teriflunomide.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Teriflunomide.
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Teriflunomide.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Teriflunomide.
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Teriflunomide.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Teriflunomide.
MetipranololTeriflunomide may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Teriflunomide.
MetoprololTeriflunomide may decrease the antihypertensive activities of Metoprolol.
MetrizamideTeriflunomide may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Teriflunomide.
MianserinThe serum concentration of Mianserin can be decreased when it is combined with Teriflunomide.
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Teriflunomide.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Teriflunomide.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Teriflunomide.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Teriflunomide.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Teriflunomide.
MorphineThe metabolism of Morphine can be decreased when combined with Teriflunomide.
muraglitazarThe serum concentration of muraglitazar can be decreased when it is combined with Teriflunomide.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Teriflunomide.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Teriflunomide.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Teriflunomide.
NabumetoneThe serum concentration of Nabumetone can be decreased when it is combined with Teriflunomide.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Teriflunomide.
NadololTeriflunomide may decrease the antihypertensive activities of Nadolol.
NadroparinTeriflunomide may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Teriflunomide.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Teriflunomide.
NaproxenThe serum concentration of Naproxen can be decreased when it is combined with Teriflunomide.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Teriflunomide.
NatalizumabThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Natalizumab.
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Teriflunomide.
NeomycinTeriflunomide may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Teriflunomide.
NetilmicinTeriflunomide may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Teriflunomide.
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Teriflunomide.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Teriflunomide.
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Teriflunomide.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Teriflunomide.
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Teriflunomide.
Nitric OxideThe serum concentration of Nitric Oxide can be decreased when it is combined with Teriflunomide.
NitrofurantoinThe serum concentration of Nitrofurantoin can be increased when it is combined with Teriflunomide.
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Teriflunomide.
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Teriflunomide.
OlmesartanThe serum concentration of Olmesartan can be increased when it is combined with Teriflunomide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Teriflunomide.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Teriflunomide.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Teriflunomide.
OlsalazineTeriflunomide may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Teriflunomide.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Teriflunomide.
OmbitasvirThe metabolism of Ombitasvir can be decreased when combined with Teriflunomide.
OmeprazoleThe serum concentration of Omeprazole can be decreased when it is combined with Teriflunomide.
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Teriflunomide.
OrgoteinThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Orgotein.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Teriflunomide.
OtamixabanTeriflunomide may increase the anticoagulant activities of Otamixaban.
OuabainThe serum concentration of Ouabain can be increased when it is combined with Teriflunomide.
OxaliplatinThe serum concentration of Oxaliplatin can be decreased when it is combined with Teriflunomide.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Teriflunomide.
OxprenololTeriflunomide may decrease the antihypertensive activities of Oxprenolol.
OxtriphyllineThe serum concentration of Oxtriphylline can be decreased when it is combined with Teriflunomide.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Teriflunomide.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Teriflunomide.
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Teriflunomide.
PamidronateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Pamidronate.
PantoprazoleThe serum concentration of Pantoprazole can be decreased when it is combined with Teriflunomide.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Teriflunomide.
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Teriflunomide.
ParomomycinTeriflunomide may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Teriflunomide.
PenbutololTeriflunomide may decrease the antihypertensive activities of Penbutolol.
PenicillamineThe serum concentration of Penicillamine can be increased when it is combined with Teriflunomide.
PentamidineThe serum concentration of Pentamidine can be decreased when it is combined with Teriflunomide.
Pentosan PolysulfateTeriflunomide may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllineThe serum concentration of Pentoxifylline can be decreased when it is combined with Teriflunomide.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Teriflunomide.
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Teriflunomide.
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Teriflunomide.
PhenindioneTeriflunomide may increase the anticoagulant activities of Phenindione.
PhenprocoumonTeriflunomide may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Teriflunomide.
PhenytoinThe metabolism of Phenytoin can be decreased when combined with Teriflunomide.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Teriflunomide.
PimozideThe serum concentration of Pimozide can be decreased when it is combined with Teriflunomide.
PindololTeriflunomide may decrease the antihypertensive activities of Pindolol.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Teriflunomide.
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Teriflunomide.
PiretanideTeriflunomide may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Teriflunomide.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Teriflunomide.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Teriflunomide.
PlicamycinTeriflunomide may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Teriflunomide.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Teriflunomide.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Teriflunomide.
PractololTeriflunomide may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Teriflunomide.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Teriflunomide.
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Teriflunomide.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Teriflunomide.
PrimaquineThe serum concentration of Primaquine can be decreased when it is combined with Teriflunomide.
ProbenecidThe serum concentration of Teriflunomide can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Teriflunomide.
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Teriflunomide.
PromazineThe serum concentration of Promazine can be decreased when it is combined with Teriflunomide.
PropacetamolThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Propacetamol.
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Teriflunomide.
PropofolThe serum concentration of Propofol can be decreased when it is combined with Teriflunomide.
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Teriflunomide.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Teriflunomide.
Protein CTeriflunomide may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeTeriflunomide may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Teriflunomide.
PuromycinTeriflunomide may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PyrazinamideThe serum concentration of Pyrazinamide can be decreased when it is combined with Teriflunomide.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Teriflunomide.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Teriflunomide.
QuinidineThe metabolism of Quinidine can be decreased when combined with Teriflunomide.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Teriflunomide.
Rabies vaccineThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Rabies vaccine.
RamelteonThe serum concentration of Ramelteon can be decreased when it is combined with Teriflunomide.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Teriflunomide.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Teriflunomide.
RasagilineThe serum concentration of Rasagiline can be decreased when it is combined with Teriflunomide.
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Teriflunomide.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Teriflunomide.
ResveratrolThe serum concentration of Resveratrol can be decreased when it is combined with Teriflunomide.
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Teriflunomide.
ReviparinTeriflunomide may increase the anticoagulant activities of Reviparin.
RibostamycinTeriflunomide may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RifabutinThe serum concentration of Rifabutin can be decreased when it is combined with Teriflunomide.
RifampicinThe metabolism of Rifampicin can be decreased when combined with Teriflunomide.
RiluzoleThe serum concentration of Riluzole can be decreased when it is combined with Teriflunomide.
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Teriflunomide.
RisedronateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Risedronate.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Teriflunomide.
RivaroxabanTeriflunomide may increase the anticoagulant activities of Rivaroxaban.
RizatriptanThe serum concentration of Rizatriptan can be decreased when it is combined with Teriflunomide.
RofecoxibThe serum concentration of Rofecoxib can be decreased when it is combined with Teriflunomide.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Teriflunomide.
RoflumilastRoflumilast may increase the immunosuppressive activities of Teriflunomide.
RolapitantThe serum concentration of Teriflunomide can be increased when it is combined with Rolapitant.
RopiniroleThe serum concentration of Ropinirole can be decreased when it is combined with Teriflunomide.
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Teriflunomide.
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Teriflunomide.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Teriflunomide.
RotigotineThe serum concentration of Rotigotine can be decreased when it is combined with Teriflunomide.
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Teriflunomide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Teriflunomide.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Teriflunomide.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Teriflunomide.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Teriflunomide.
SelegilineThe serum concentration of Selegiline can be decreased when it is combined with Teriflunomide.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Teriflunomide.
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Teriflunomide.
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Teriflunomide.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Teriflunomide.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Teriflunomide.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Teriflunomide.
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Teriflunomide.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Teriflunomide.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Teriflunomide.
SotalolTeriflunomide may decrease the antihypertensive activities of Sotalol.
SpectinomycinTeriflunomide may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Teriflunomide.
SpironolactoneTeriflunomide may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Teriflunomide.
StavudineThe serum concentration of Stavudine can be increased when it is combined with Teriflunomide.
StreptomycinTeriflunomide may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinTeriflunomide may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Teriflunomide.
SulfasalazineThe serum concentration of Sulfasalazine can be increased when it is combined with Teriflunomide.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Teriflunomide.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Teriflunomide.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Teriflunomide.
SulodexideTeriflunomide may increase the anticoagulant activities of Sulodexide.
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Teriflunomide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Teriflunomide.
TacrineThe serum concentration of Tacrine can be decreased when it is combined with Teriflunomide.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Teriflunomide.
TacrolimusTeriflunomide may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Teriflunomide.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Teriflunomide.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Teriflunomide.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Teriflunomide.
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Teriflunomide.
Technetium Tc 99m MebrofeninThe serum concentration of Technetium Tc 99m Mebrofenin can be increased when it is combined with Teriflunomide.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Technetium Tc-99m Medronate.
TelithromycinThe serum concentration of Telithromycin can be decreased when it is combined with Teriflunomide.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Teriflunomide.
TemafloxacinThe serum concentration of Temafloxacin can be decreased when it is combined with Teriflunomide.
TemazepamThe metabolism of Temazepam can be decreased when combined with Teriflunomide.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Teriflunomide.
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Teriflunomide.
TenofovirThe serum concentration of Tenofovir can be increased when it is combined with Teriflunomide.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Teriflunomide.
TepoxalinThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Tepoxalin.
TerbinafineThe serum concentration of Terbinafine can be decreased when it is combined with Teriflunomide.
TestosteroneThe serum concentration of Testosterone can be increased when it is combined with Teriflunomide.
ThalidomideThe serum concentration of Thalidomide can be decreased when it is combined with Teriflunomide.
TheobromineThe serum concentration of Theobromine can be decreased when it is combined with Teriflunomide.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Teriflunomide.
ThiabendazoleThe serum concentration of Thiabendazole can be decreased when it is combined with Teriflunomide.
ThioridazineThe serum concentration of Thioridazine can be decreased when it is combined with Teriflunomide.
ThiothixeneThe serum concentration of Thiothixene can be decreased when it is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Teriflunomide.
TiludronateThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Tiludronate.
TimololTeriflunomide may decrease the antihypertensive activities of Timolol.
TizanidineThe serum concentration of Tizanidine can be decreased when it is combined with Teriflunomide.
TobramycinTeriflunomide may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TofacitinibTeriflunomide may increase the immunosuppressive activities of Tofacitinib.
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Teriflunomide.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Teriflunomide.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Teriflunomide.
TorasemideThe metabolism of Torasemide can be decreased when combined with Teriflunomide.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Teriflunomide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Teriflunomide.
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Teriflunomide.
TrastuzumabTrastuzumab may increase the neutropenic activities of Teriflunomide.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Teriflunomide.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Teriflunomide.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Teriflunomide.
TriamtereneThe serum concentration of Triamterene can be decreased when it is combined with Teriflunomide.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Teriflunomide.
TrifluoperazineThe serum concentration of Trifluoperazine can be decreased when it is combined with Teriflunomide.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Teriflunomide.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Teriflunomide.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Teriflunomide.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Teriflunomide.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Teriflunomide.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Teriflunomide.
ValsartanThe serum concentration of Valsartan can be increased when it is combined with Teriflunomide.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Teriflunomide.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Teriflunomide.
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Teriflunomide.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Teriflunomide.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Teriflunomide.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Teriflunomide.
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Teriflunomide.
XimelagatranTeriflunomide may increase the anticoagulant activities of Ximelagatran.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Teriflunomide.
ZalcitabineThe serum concentration of Zalcitabine can be increased when it is combined with Teriflunomide.
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Teriflunomide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Teriflunomide.
ZileutonThe serum concentration of Zileuton can be decreased when it is combined with Teriflunomide.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Teriflunomide.
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Teriflunomide.
Zoledronic acidThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Zoledronic acid.
ZolmitriptanThe serum concentration of Zolmitriptan can be decreased when it is combined with Teriflunomide.
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Teriflunomide.
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Teriflunomide.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Teriflunomide.
Food Interactions
  • Food does not affect teriflunomide pharmacokinetics, so take with or without food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Ubiquinone binding
Specific Function:
Catalyzes the conversion of dihydroorotate to orotate with quinone as electron acceptor.
Gene Name:
DHODH
Uniprot ID:
Q02127
Molecular Weight:
42866.93 Da
References
  1. Palmer AM: Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis. Curr Opin Investig Drugs. 2010 Nov;11(11):1313-23. [PubMed:21157651 ]
  2. Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA: The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry. 1996 Jan 30;35(4):1270-3. [PubMed:8573583 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Kis E, Nagy T, Jani M, Molnar E, Janossy J, Ujhellyi O, Nemet K, Heredi-Szabo K, Krajcsi P: Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis. 2009 Jul;68(7):1201-7. doi: 10.1136/ard.2007.086264. Epub 2008 Apr 8. [PubMed:18397960 ]
Comments
comments powered by Disqus
Drug created on May 19, 2013 20:55 / Updated on September 24, 2016 02:17